tiprankstipranks
Recce Pharmaceuticals Director Increases Stake with New Options
Company Announcements

Recce Pharmaceuticals Director Increases Stake with New Options

Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.

Pick the best stocks and maximize your portfolio:

Recce Pharmaceuticals Ltd. announced a change in the interests of Director Dr. John Prendergast, who acquired 2,650,000 unlisted options under the company’s Employee Incentive Plan. These options have an estimated value of $0.244 each, calculated using the Black Scholes valuation method, highlighting the director’s increased stake in the company.

For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskRecce Pharmaceuticals Advances Phase 3 Trial in Indonesia
TipRanks Australian Auto-Generated NewsdeskRecce Pharmaceuticals Awaits Key Approval Announcement
TipRanks Australian Auto-Generated NewsdeskRecce Pharmaceuticals Highlights Risks and Cautions Investors
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App